OS Therapies Business Summary

OS Therapies Inc (OSTX) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of immunotherapies for osteosarcoma and other solid tumors. The company operates through two primary technology segments: its lead listeria-based immunotherapy platform (OST-HER2) and its proprietary tunable Antibody Drug Conjugate (tADC) platform. Currently pre-revenue, OS Therapies’ near-term monetization strategy centers on the potential sale of a Priority Review Voucher (PRV), valued at approximately $160 million, contingent upon the FDA’s accelerated approval of its lead candidate, OST-HER2, by September 30, 2026. Long-term revenue is projected from global product sales in the U.S., U.K., and E.U. beginning in 2027, as well as potential licensing agreements for its tADC platform. Within the competitive landscape, the company positions itself as a global leader in listeria-based oncology treatments, competing against established players such as Jazz Pharmaceuticals, Kite Pharma, and Advanced Accelerator Applications by targeting high-unmet-need niches like rare pediatric metastatic bone cancers. The leadership team is anchored by Founder, Chairman, and CEO Paul A. Romness, MPH, a biopharma veteran with over 25 years of experience and a track record of nine major product launches at industry giants like Johnson & Johnson and Amgen. Technical development is led by Dr. Robert G. Petit II, who serves as both Chief Medical Officer and Chief Scientific Officer; as the founding scientist of the OST-HER2 program, Dr. Petit brings extensive expertise in oncology and immunology from previous C-suite roles in the biotech sector. The executive suite also includes CFO Christopher P. Acevedo, a specialist in M&A and business strategy, and Chief Business Officer Gerald Commissiong, who has raised over $70 million in capital throughout his career. The company is backed by notable institutional investors including CM Management LLC, Vanguard Group, and Geode Capital Management, while its board is strengthened by the presence of strategic advisors like Dr. Jutta Wanner, the founding scientist of the company’s tADC technology.